Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of HRS-5965 tablets in primary IgA nephropathy
CTR20233714Phase 2Completed
- Sponsor
- Chengdu Shengdi
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-5965 in IgA nephropathy (IgAN), sponsored by Chengdu Shengdi. Started Feb 2024; status: completed.
02
Drugs
HRS-5965
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20233714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233714.